NASDAQ
117.59USD
-2.45 (-2.04%)
We have scored 39 news catalysts on Incyte Corporation (INCY) over the past 12 months. The biggest single-day move next to one of them came Apr 30, 2026, when INCY closed −3.9%: “Syndax Reports First Quarter 2026 Financial Results and Provides Business Update”. Coverage across the window leans positive (average ticker sentiment +0.57). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
24B
P/E
—
EPS
—
Beta
0.78
52W range
89.25-132.6
Day range
117.27–121.05
Open
118.96
Prev close
120.04
Volume
2.2M
Avg volume
1.7M
Dividend
0.00
IPO
1993-11-04
Analysts publish price targets on INCY, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
22 analyst price targets from $94 to $155
as of 2026-09-22
The market is within 3% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Incyte Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for INCY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
The price sits at the 55th percentile of 22 published models, essentially matching the median target, meaning the market broadly endorses a scenario where the rapid growth of the past year decelerates to a crawl.
What the disagreement turns on
The central question is whether Incyte's newer products and pipeline can actually replace Jakafi's dominance with high growth, or if the market is correct to assume the company is destined for low single-digit expansion; unit volume data for Opzelura and the newer brands can test this, but pipeline clinical success cannot be measured with the wired tools.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $125 on 2026-09-22 — the quote has since moved -6%, so read this as a record of what was priced in then, not now.
